Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women’s Health Initiative
- 20 June 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 33 (9) , 1203-1210
Abstract
Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.Keywords
All Related Versions
Funding Information
- National Heart, Lung, and Blood Institute (75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005)
This publication has 41 references indexed in Scilit:
- Aspirin Use to Prevent Cardiovascular DiseaseJAMA, 2022
- Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019Annals of Oncology, 2020
- Non-steroidal anti-inflammatory drugs and cancer risk in women: Results from the Women's Health InitiativeInternational Journal of Cancer, 2014
- Non-linear dose–response relationship between cigarette smoking and pancreatic cancer risk: Evidence from a meta-analysis of 42 observational studiesEuropean Journal of Cancer, 2014
- Inflammation and pancreatic cancer: disease promoter and new therapeutic targetJournal of Gastroenterology, 2013
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2011
- Body mass index and pancreatic cancer risk: A meta‐analysis of prospective studiesInternational Journal of Cancer, 2007
- The women's health initiative recruitment methods and resultsAnnals of Epidemiology, 2003
- The women's health initiative postmenopausal hormone trials: overview and baseline characteristics of participantsAnnals of Epidemiology, 2003
- The women's health initiative dietary modification trial: overview and baseline characteristics of participantsAnnals of Epidemiology, 2003